| |
Wednesday, April 9, 2025 | 10am ET / 7am PT Learn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot!
|
|
Today’s Big NewsMar 31, 2025 |
|
Wednesday, April 9, 2025 | 11am ET / 8am PT Health systems around the globe face a difficult paradox: delivering more care with fewer resources. In this exclusive webinar, our expert panel will explore how AI-based solutions are addressing these challenges with real-world examples, experience, and published outcomes in ASCO and Nature. Register now.
|
|
| By Fraiser Kansteiner In resigning as director of the FDA’s Center for Biologics Evaluation and Research, Peter Marks, M.D., Ph.D., blasted the promotion of vaccine disinformation under new HHS Secretary Robert F. Kennedy Jr. |
|
|
|
By Darren Incorvaia While coming back down from 2023’s dizzying high, Merck & Co. still managed to hang on to the top spot of our annual research and development budgets list. |
By Gabrielle Masson Christopher Corsico, M.D., has left GSK to become Sanofi’s global head of development, effective immediately. |
By Kevin Dunleavy Merck revealed data from a phase 3 study of pulmonary arterial hypertension drug Winrevair, which showed it reduced the risk of all-cause death, lung transplantation and hospitalization by 76% versus placebo, despite maximal background therapy. |
|
Thursday, April 10, 2025 | 11am ET / 8am PT Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. However, the complexities pose key challenges. In this webinar, learn how to choose the right production platform for achieving commercial timelines and managing manufacturing costs. Register now.
|
|
By Andrea Park Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that the company engaged in misleading marketing tactics for two of its HIV meds, a judge has upped the penalty more than tenfold. |
By Conor Hale Cologuard is getting an upgrade after 10 years on the market. Exact Sciences said the addition of new genetic biomarkers to the stool DNA test has cut its rate of false positives. |
By Zoey Becker Imfinzi is the first immunotherapy cleared in the U.S. to treat muscle-invasive bladder cancer patients before and after bladder removal surgery, making for a new treatment option in a disease with high rates of recurrence. |
By James Waldron AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks at its highest dose, hitting the goal of a phase 2 trial in patients with a lipid disorder. |
By Angus Liu A rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio, and the company's board is "carefully reviewing" the offer, which values the biotech 50% higher than the original deal. |
By Darren Incorvaia AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its programs spanning multiple therapeutic areas. |
By Andrea Park As the college basketball March Madness tournament gets underway, so too does Fierce Pharma Marketing’s annual #FierceMadness competition. |
By Conor Hale The Revolution Vibe scanner includes what the company describes as unlimited one-beat cardiac imaging—capturing low-dose, full-organ pictures fast enough so they can be used to clearly assess moving valves and clogged arteries across the pulsing heart. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we hear from Nada Hanafi, co-founder of MedTech Color, about the importance of diversity in healthcare settings. |
|
|---|
|
|
|
Antibody-drug conjugates (ADCs) and radioisotope therapies (RITs) offer targeted therapies that effectively attack tumor cells while minimizing harm to surrounding healthy tissue. However, the right design of ADC and RIT trials is critical. Access this report to learn about the pivotal role of advanced medical imaging. Download here.
|
|
| ResearchWe interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
